

## Ongoing Disclosure Notice

## Disclosure of Directors and Senior Managers Relevant Interests

*Sections 297(2) and 298(2), Financial Markets Conduct Act 2013*

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	29 September 2023
Date of last disclosure:	13 September 2023

**Director or senior manager giving disclosure**

Full name(s):	Andrew Robert Donald Somervell
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Vice President - Products & Technology

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:	(a) Options to acquire Ordinary Shares
Nature of the affected relevant interest(s):	(b) Ordinary Shares
<b>For that relevant interest</b>	Beneficial
Number held in class before acquisition or disposal:	(a) 154,649 Options
Number held in class after acquisition or disposal:	(b) 98,631 Ordinary Shares
Current registered holder(s):	(a) 117,027 Options
Registered holder(s) once transfers are registered:	(b) 103,490 Ordinary Shares
	Andrew Robert Donald Somervell
	Andrew Robert Donald Somervell

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	
Class of underlying financial products:	
<b>Details of affected derivative-</b>	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Two
<b>Details of transactions requiring disclosure-</b>	
Date of transaction:	(a) 26 September 2023 (b) 26 September 2023
Nature of transaction:	(a) Cancellation of Options and Issue of Ordinary Shares (b) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	(a) Exercise price of \$17.21 per Share (b) \$72,105

